CoChat

Chidamide (CS055/HBI-8000): a new histone deacetylase inhibitor of the benzamide class with antitumor activity and the ability to enhance immune cell-mediated tumor cell cytotoxicity

Ning, Zhi-Qiang, Li, Zhi-Bin, Newman, Michael J., Shan, Song, Wang, Xin-Hao, Pan, De-Si, Zhang, Jin, Dong, Mei, Du, Xin, Lu, Xian-Ping · 2012 · Cancer Chemotherapy and Pharmacology

The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.

Abstract

Purpose Chidamide (CS055/HBI-8000) is a new histone deacetylase (HDAC) inhibitor of the benzamide class currently under clinical development in cancer indications. This study reports the in vitro and in vivo antitumor characteristics of the compound.Methods Selectivity and potency of chidamide in inhibition of HDAC isotypes were analyzed by using a panel of human recombinant HDAC proteins. Tumor cell lines either in culture or inoculated in nude mice were used for the evaluation of the compound's antitumor activity. To investigate the immune cell-mediated antitumor effect, isolated peripheral blood mononuclear cells from healthy donors were treated with chidamide, and cytotoxicity and expression of relevant surface proteins were analyzed. Microarray gene expression studies were performed on peripheral white blood cells from two T-cell lymphoma patients treated with chidamide.Results Chidamide was found to be a low nanomolar inhibitor of HDAC1, 2, 3, and 10, the HDAC isotypes well documented to be associated with the malignant phenotype. Significant and broad spectrum in vitro and in vivo antitumor activity, including a wide therapeutic index, was observed. Chidamide was also shown to enhance the cytotoxic effect of human peripheral mononuclear cells ex vivo on K562 target cells, accompanied by the upregulation of proteins involved in NK cell functions. Furthermore, the expression of a number of genes involved in immune cell-mediated antitumor activity was observed to be upregulated in peripheral white blood cells from two T-cell lymphoma patients who responded to chidamide administration.Conclusions The results presented in this study provide evidence that chidamide has potential applicability for the treatment of a variety of tumor types, either as a single agent or in combination therapies.

Overview

Integrity signals

Registry

Crossref · 10.1007/s00280-011-1766-x

Cites

22 of 22 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 22 references

Cited by

See all 320

Metadata

Authors
Ning, Z.-Q., Li, Z.-B., Newman, M. J., Shan, S., Wang, X.-H., Pan, D.-S., Zhang, J., Dong, M., Du, X., & Lu, X.-P.
Affiliations
  • HUYABIO International, LLC (United States) (US)
  • Shenzhen Chipscreen Biosciences Co. (CN)
  • Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
Venue
Cancer Chemotherapy and Pharmacology
Published
2011-11-12
Volume
69
Issue
4
Pages
901-909
ISSN
  • 0344-5704 (ISSN-L)
  • 1432-0843
OpenAlex
W2033582950
Cited by
303
References
22
Citations by year
2026: 19 · 2025: 27 · 2024: 34 · 2023: 33 · 2022: 34 · 2021: 43 · 2020: 33 · 2019: 18 · 2018: 21 · 2017: 12 · 2016: 12 · 2015: 4 · 2014: 4 · 2013: 4 · 2012: 5
FWCI
1.82
Type
journal article
Language
en
Open access
closed
Licence
www.springer.com/tdm (tdm)
Locations
  • Cancer Chemotherapy and Pharmacology (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Histone Deacetylase Inhibitors Research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
  • Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
Keywords
chidamide, histone deacetylase inhibitors, HDAC1, HDAC2, HDAC3, HDAC10, anticancer activity, NK cell function, T-cell lymphoma, K562 cells, peripheral blood mononuclear cells, gene expression profiling, combination therapy
MeSH terms
Acetylation, Aminopyridines, Animals, Benzamides, Cytotoxicity, Immunologic, Female, Histone Deacetylases, Histones, Humans, Immunity, Cellular, Isoenzymes, Killer Cells, Natural, Mice, Inbred BALB C, Mice, Nude, Neoplasms, Gene Expression, Lymphoma, T-Cell, K562 Cells, Xenograft Model Antitumor Assays, Cell Line, Tumor, Cell Growth Processes, Mice, Histone Deacetylase Inhibitors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Chidamide (CS055/HBI-8000): a new histone deacetylase inhibitor of the benzamide class with antitumor activity and the ability to enhance immune cell-mediated tumor cell cytotoxicity. https://app.cochat.ai/papers/10.1007/s00280-011-1766-x
The paper
Ning, Z.-Q., Li, Z.-B., Newman, M. J., Shan, S., Wang, X.-H., Pan, D.-S., Zhang, J., Dong, M., Du, X., & Lu, X.-P. (2012). Chidamide (CS055/HBI-8000): a new histone deacetylase inhibitor of the benzamide class with antitumor activity and the ability to enhance immune cell-mediated tumor cell cytotoxicity. Cancer Chemotherapy and Pharmacology. https://doi.org/10.1007/s00280-011-1766-x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.